• Pulse Biosciences, Inc. recently reported that for the second quarter and first half of 2026 its net loss widened to US$24.66 million and US$43.24 million respectively, with basic loss per share from continuing operations increasing to US$0.36 for the quarter and US$0.63 for the half year.
• On the same day, the company also filed for a US$75 million at‑the‑market follow-on equity offering, highlighting both its increased cash needs and its reliance on equity financing to support ongoing development of its nanosecond pulse field ablation platforms.
• Next, we will examine how the larger losses and planned US$75 million equity raise may reshape Pulse Biosciences’ investment narrative.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Pulse Biosciences Investment Narrative Recap

To own Pulse Biosciences today, you need to believe its nanosecond pulse field ablation platforms can convert heavy R&D spending into meaningful, procedure driven revenue. The wider Q2 and first half 2026 losses, combined with the planned US$75 million at the market equity raise, sharpen the near term focus on cash use and dilution risk, but do not fundamentally change the core clinical trial and commercialization milestones that still look like the key short term catalysts.

Among recent updates, the late July announcement that the NANOPULSE AF study has passed its enrollment midpoint stands out next to the new loss figures and equity program. Progress in this atrial fibrillation feasibility and safety study is central to the nPulse Cardiac Catheter story, and the additional equity capacity now filed sits against that backdrop of advancing but still non revenue generating clinical work.

Yet while early bullish analysts once pencilled in revenue growth above 300 percent a year, the combination of deeper losses and fresh equity capacity highlights cash burn and dilution risks that investors should be aware of...

Pulse Biosciences' narrative projects $58.5 million revenue and $7.1 million earnings by 2029. This requires 266.8% yearly revenue growth and an $87.2 million earnings increase from -$80.1 million today.

Uncover how Pulse Biosciences' forecasts yield a $41.00 fair value, a 8% downside to its current price.

Exploring Other Perspectives

Before this setback, the most optimistic analysts were assuming revenue could reach about US$52 million by 2029, which is far more bullish than consensus and may need to be reconsidered in light of the larger losses and fresh US$75 million equity filing.

Explore another fair value estimate on Pulse Biosciences - why the stock might be worth 8% less than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Pulse Biosciences research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Pulse Biosciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Pulse Biosciences' overall financial health at a glance.

No Opportunity In Pulse Biosciences?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.